Use of acellular pertussis vaccines in the United States: can we do better?

References

• Kilgore PE, Salim AM, Zervos MJ, et al. Pertussis: microbiology, disease, treatment, and prevention. Clin Microbiol Rev. 2016;29(3):449–486.
   PubMed Web of Science ®Google Scholar
• Cherry JD. Epidemic pertussis in 2012 – the resurgence of a vaccine-preventable disease. N Engl J Med. 2012;367(9):785–787.
   PubMed Web of Science ®Google Scholar
• Klein NP. Licensed pertussis vaccines in the United States. History and current state. Hum Vaccin Immunother. 2014;10(9):2684–2690.
   PubMed Web of Science ®Google Scholar
• Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR–7):1–25.
   Google Scholar
• Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR–3):1–34.
   PubMedGoogle Scholar
• Notes from the field: pertussis – California, January–June 2010. MMWR Morb Mortal Wkly Rep. 2010;59(26):817.
   Google Scholar
• Amirthalingam G. Strategies to control pertussis in infants. Arch Dis Child. 2013;98(7):552–555.
   PubMed Web of Science ®Google Scholar
• Klein NP, Bartlett J, Fireman B, et al. Waning Tdap effectiveness in adolescents. Pediatrics. 2016;137(3):1–9.
   Web of Science ®Google Scholar
• Skoff TH, Martin SW. Impact of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccinations on reported pertussis cases among those 11 to 18 years of age in an era of waning pertussis immunity: a follow-up analysis. JAMA Pediatr. 2016;170(5):453–458.
   PubMed Web of Science ®Google Scholar
• Domenech de Cellès M, Magpantay FMG, King AA, et al. The pertussis enigma: reconciling epidemiology, immunology and evolution. Proc Biol Sci. 2016 Jan 13;283(1822). pii: 20152309. doi: 10.1098/rspb.2015.2309.
   Web of Science ®Google Scholar
• Wendelboe AM, Van Rie A, Salmaso S, et al. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24(5 Suppl):S58–61.
   PubMedGoogle Scholar
• Klein NP, Bartlett J, Rowhani-Rahbar A, et al. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med. 2012;367(11):1012–1019.
   PubMed Web of Science ®Google Scholar
• Misegades LK, Winter K, Kathleen Harriman K, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA. 2012;308(20):2126–2132.
   PubMed Web of Science ®Google Scholar
• Tartof SY, Lewis M, Kenyon C, et al. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics. 2013;131(4):e1047–1052.
   PubMed Web of Science ®Google Scholar
• McGirr A, Fisman DN. Duration of pertussis immunity after DTaP immunization: a meta-analysis. Pediatrics. 2015;135(2):331–343.
   PubMed Web of Science ®Google Scholar
• Schwartz KL, Kwong JC, Deeks SL, et al. Effectiveness of pertussis vaccination and duration of immunity. CMAJ. 2016;188:E399–E406.
   Web of Science ®Google Scholar
• Klein NP, Bartlett J, Fireman B, et al. Waning protection following 5 doses of a 3-component diphtheria, tetanus, and acellular pertussis vaccine. Vaccine. 2017;35(26):3395–3400.
   PubMed Web of Science ®Google Scholar
• Reagan-Steiner S, Yankey D, Jeyarajah J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years – United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(29):784–792.
   PubMed Web of Science ®Google Scholar
• Ward JI, Cherry JD, Chang S-J, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005;353(15):1555–1563.
   PubMed Web of Science ®Google Scholar
• Wei SC, Tatti K, Cushing K, et al. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. Clin Infect Dis. 2010;51(3):315–321.
   PubMed Web of Science ®Google Scholar
• Rank C, Quinn HE, McIntyre PB. Pertussis vaccine effectiveness after mass immunization of high school students in Australia. Pediatr Infect Dis J. 2009;28(2):152–153.
   PubMed Web of Science ®Google Scholar
• Baxter R, Bartlett J, Rowhani-Rahbar A, et al. Effectiveness of pertussis vaccines for adolescents and adults: case-control study. BMJ. 2013;347:f4249.
   PubMed Web of Science ®Google Scholar
• Terranella A, Rea V, Griffith M, et al. Vaccine effectiveness of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine during a pertussis outbreak in Maine. Vaccine. 2016;34(22):2496–2500.
   PubMed Web of Science ®Google Scholar
• Koepke R, Eickhoff JC, Ayele RA, et al. Estimating the effectiveness of tetanus-diphtheria-acellular pertussis vaccine (Tdap) for preventing pertussis: evidence of rapidly waning immunity and difference in effectiveness by Tdap brand. J Infect Dis. 2014;210(6):942–953.
   PubMed Web of Science ®Google Scholar
• Acosta AM, DeBolt C, Tasslimi A, et al. Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic. Pediatrics. 2015;135(6):981–989.
   PubMed Web of Science ®Google Scholar
• Hallander HO, Nilsson L, Gustafsson L. Is adolescent pertussis vaccination preferable to natural booster infections? Expert Rev Clin Pharmacol. 2011;4(6):705–711.
   PubMedGoogle Scholar
• Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women – Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep. 2013;62(7):131–135.
   PubMed Web of Science ®Google Scholar
• Amirthalingam G, Campbell H, Ribeiro S, et al. Sustained effectiveness of the maternal pertussis immunization program in England 3 years following introduction. Clin Infect Dis. 2016;63(suppl 4):S236–S243.
   PubMed Web of Science ®Google Scholar
• Baxter R, Bartlett J, Fireman B, et al. Effectiveness of vaccination during pregnancy to prevent infant pertussis. Pediatrics. 2017;139(5):e20164091.
   PubMed Web of Science ®Google Scholar
• Kamiya H, Cho BH, Messonnier ML, et al. Impact and cost-effectiveness of a second tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine dose to prevent pertussis in the United States. Vaccine. 2016;34(15):1832–1838.
   PubMed Web of Science ®Google Scholar
• Mascart F, Hainaut M, Peltier A, et al. Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine. 2007;25(2):391–398.
   PubMed Web of Science ®Google Scholar
• Ryan M, Murphy G, Ryan E, et al. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology. 1998;93(1):1–10.
   PubMed Web of Science ®Google Scholar
• Bolotin S, Harvill ET, Crowcroft NS. What to do about pertussis vaccines? Linking what we know about pertussis vaccine effectiveness, immunology and disease transmission to create a better vaccine. Pathog Dis. 2015;73(8):ftv057.
   PubMed Web of Science ®Google Scholar
• DeAngelis H, Scarpino SV, Fitzpatrick MC, et al. Epidemiological and economic effects of priming with the whole-cell Bordetella pertussis vaccine. JAMA Pediatr. 2016;170(5):459–465.
   PubMed Web of Science ®Google Scholar
• Klein NP, Bartlett J, Fireman B, et al. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics. 2013;131(6):e1716–1722.
   PubMed Web of Science ®Google Scholar
• Liko J, Robison SG, Cieslak PR. Priming with whole-cell versus acellular pertussis vaccine. N Engl J Med. 2013;368(6):581–582.
   PubMed Web of Science ®Google Scholar
• Sheridan SL, Ware RS, Grimwood K, et al. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA. 2012;308(5):454–456.
   PubMed Web of Science ®Google Scholar
• Choi YH, Campbell H, Amirthalingam G, et al. Investigating the pertussis resurgence in England and Wales, and options for future control. BMC Med. 2016;14(1):121.
   PubMed Web of Science ®Google Scholar
• Snelling T, McIntyre P. Modeling the effects of priming with the whole-cell Bordetella pertussis vaccine. JAMA Pediatr. 2016;170(12):1228–1229.
   PubMed Web of Science ®Google Scholar
• Sawyer MH. The pertussis problem and a possible solution: will parents go along? JAMA Pediatr. 2016;170(5):421–422.
   PubMed Web of Science ®Google Scholar
• Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci U S A. 2014;111(2):787–792.
   PubMed Web of Science ®Google Scholar
• Hallander HO, Advani A, Donnelly D, et al. Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J Clin Microbiol. 2005;43(6):2856–2865.
   PubMed Web of Science ®Google Scholar
• Breakwell L, Kelso P, Finley C, et al. Pertussis vaccine effectiveness in the setting of pertactin-deficient pertussis. Pediatrics. 2016;137(5):e20153973.
   PubMed Web of Science ®Google Scholar
• Halperin BA, MacDougall D, MacKinnon-Cameron D, et al. Universal tetanus, diphtheria, acellular pertussis (Tdap) vaccination of adults: what the Canadian public knows and wants to know. Vaccine. 2015;33(48):6840–6848.
   PubMed Web of Science ®Google Scholar